NCT06815380View on ClinicalTrials.gov

A Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations in Participants With Moderate-to-Severe Atopic Dermatitis

RecruitingOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

January 23, 2025

Primary Completion Date

March 31, 2029

Study Completion Date

March 31, 2029

Conditions
Atopic DermatitisEczema
Interventions
OTHER

No Intervention

This is non-interventional study.

Trial Locations (1)

Unknown

RECRUITING

Aarhus University Hospital, Aarhus

Sponsors

Lead Sponsor

Almirall, S.A.
All Listed Sponsors
lead

Almirall, S.A.

INDUSTRY

NCT06815380 - A Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations in Participants With Moderate-to-Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter